SequelConnect is a diabetes management program for employers, health plans, and benefits partners, with a focus on high-cost members who use insulin. It does not claim to replace existing diabetes programs; instead, it is positioned as an add-on module that helps members access the twiist™ Automated Insulin Delivery (AID) system and improve adoption through virtual care, training, and support.
Based on publicly available materials, SequelConnect covers targeted member outreach, digital enrollment, virtual care, prescription pathways, virtual training, and 24/7 support. It is well suited for benefits teams looking to package “device + service + member engagement” into their diabetes strategy. The website says it can integrate seamlessly with existing systems and bill directly through pharmacy benefit managers (PBMs), but it does not disclose specific information about HRIS, claims, EHR, data interfaces, or APIs. It also does not explain typical SaaS capabilities such as admin dashboards, permission management, or data export.
B2B contract pricing is not public. The member-side offer is clearer: most eligible users pay $0 for the first month, then no more than $50 per month; there is no obligation to continue, and no additional per-member-per-month fee. However, the offer is limited to people in the United States who have a valid prescription and commercial insurance coverage for twiist. It does not apply to government programs such as Medicare or Medicaid, and some members with high-deductible plans may pay more. The twiist system is currently intended for insulin-deficient users such as people aged 6 and above with type 1 diabetes; type 2 indications are still being advanced.
Its strengths are clear positioning and coverage of the insulin delivery layer, which complements traditional glucose monitoring and lifestyle management. It also combines member outreach, training, support, and PBM billing, reducing implementation friction for employer benefits teams. The drawbacks are that public information is relatively marketing-oriented, with limited disclosure around security and compliance, data governance, APIs, SLAs, customer cases, or quantified outcomes. It also depends heavily on the U.S. commercial insurance system, which limits international replicability.
SequelConnect is best suited for large U.S. employers, health plans, and benefits service providers seeking to reduce adverse events and medical spending among insulin-dependent members. Access from China is unclear, and its payment, prescription, insurance, and device applicability are all strongly localized to the U.S. market. Deployment in China would typically require consideration of local internet hospitals, commercial insurance-based chronic disease management, glucose monitoring device ecosystems, and compliant alternative medical device solutions.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on sequelconnect.com official site.
sequelconnect.com is an United States SaaS Tools provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach sequelconnect.com directly.